168 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 24
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
4:08pm
label extension (OLE) study to assess the long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues in patients
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
further characterization of frataxin PD at the 25 mg dose. The OLE study is evaluating the long-term safety as well as frataxin levels following daily … 50% of the average healthy volunteer level.
The long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
of Ambulation
Completed Ph 2 Dose Exploration Study (25 & 50 mg Cohorts) Goal: Further characterize PK/PD and assess safety to inform long-term dose … Dose Cohort 1: 25 mg Cohort 2: 50 mg Key Endpoints Frataxin levels in peripheral tissue, PK, safety and tolerability; other exploratory endpoints
8-K
EX-99.1
cdylta3ptwn
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
8-K
EX-99.2
e39zx kgp
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
PRE 14A
xdiryb2
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
6plt1y
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.3
dyej0zsnxh2o2bx
11 Mar 24
Other Events
4:09pm
8-K
EX-99.1
y2q1qe yximqt4q3j
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
pai05oy2i2u7
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
xc5v3e mr00cenh
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
z896lwo
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
c9b6gqx9xsv81o 3xnl
13 Feb 24
Prospectus supplement for primary offering
4:46pm